/PRNewswire/ Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies.
Get latest articles and stories on Business at LatestLY. Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox™ platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization (CDSCO) to conduct its global, pivotal Phase 3 clinical trial (ASP-1929-301/ClinicalTrials.gov Identifier: NCT03769506) evaluating Alluminox treatment (photoimmunotherapy) using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas (HNSCC) in India, and the registration of clinical trial information with the Clinical Trial Registry of India (CTRI) has been completed (CTRI Identifier: CTRI/2023/05/052728). The study sites will include several leading medical institutions in India such as the Tata Memorial Centre and Narayana Health, and the treatment will be administered to enrolled patient
Rakuten Medical, a global biotechnology company developing and commercializing precision, cell-targeting therapies based on its proprietary Alluminox platform, today announced that the Company has been granted permission from the Indian Central Drugs Standard Control Organization CDSCO to conduct its global, pivotal Phase 3 clinical trial ASP-1929-301ClinicalTrials.gov Identifier NCT03769506 evaluating Alluminox treatment photoimmunotherapy using ASP-1929 in patients with locoregional, recurrent head and neck squamous cell carcinomas HNSCC in India, and the registration of clinical trial information with the Clinical Trial Registry of India CTRI has been completed CTRI Identifier CTRI202305052728.